Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Phase II Reactions: Acetylation Reactions

Phase II Reactions: Acetylation Reactions

Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...

What is Cancer?

What is Cancer?

Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mapping of class II HLA restriction of SepSecS-specific CD4 T cell epitopes in autoimmune hepatitis.

JHEP reports : innovation in hepatology·2026

Same author

Biallelic ARID1A Alterations: A Promising Novel Biomarker for Risk Stratification and Management in Pediatric Malignant Hepatocellular Tumors.

The American journal of surgical pathology·2026

Same author

Tetraploidy in cancer: Diagnostic and therapeutic perspectives.

Biochemical pharmacology·2026

Same author

Targeting GD2 with CAR-T Cell Therapy in Neuroblastoma: Updates, Challenges, and Future Perspectives.

Current oncology reports·2026

Same author

Coexpression of IL15 Promotes Effector Differentiation and Sustained Proliferative Capacity in ALPPL2-Specific Human CAR T Cells.

Cancer immunology research·2026

Same author

Factor VIII restores bone parameters and modulates muscle proteo-metabolome in Factor VIII knockout male mice.

Bone research·2026

Search research articles

Related Experiment Video

Updated: Jan 31, 2026

Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening

Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening

Published on: January 26, 2024

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.

Julien Fleurence¹, Sophie Fougeray¹, Meriem Bahri²

¹Inserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France; CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France; Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France.

Journal of Immunology Research

|February 4, 2017

Summary

O-Acetyl-GD2 is a novel cancer immunotherapy target. This review explores its role in tumor biology and preclinical data for anti-O-acetyl-GD2 antibodies, including CAR T-cell therapy applications.

More Related Videos

Ganglioside Extraction, Purification and Profiling

Ganglioside Extraction, Purification and Profiling

Published on: March 12, 2021

Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy

Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy

Published on: November 8, 2016

Related Experiment Videos

Last Updated: Jan 31, 2026

Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening

Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening

Published on: January 26, 2024

Ganglioside Extraction, Purification and Profiling

Ganglioside Extraction, Purification and Profiling

Published on: March 12, 2021

Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy

Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy

Published on: November 8, 2016

Area of Science:

Immunology
Oncology
Glycobiology

Background:

Gangliosides are promising cancer immunotherapy targets due to higher tumor abundance.
GD2 is a validated target antigen, with dinutuximab as an approved therapeutic antibody.
Neuropathic pain is a limitation of anti-GD2 antibody therapy.

Purpose of the Study:

To examine the role of O-Acetyl-GD2 in tumor biology.
To review preclinical data for anti-O-acetyl-GD2 monoclonal antibodies.
To discuss O-Acetyl-GD2's relevance in chimeric antigen receptor T cell therapy.

Main Methods:

Literature review of O-Acetyl-GD2 in cancer immunotherapy.
Analysis of preclinical data for anti-O-acetyl-GD2 antibodies.
Exploration of O-Acetyl-GD2's role in CAR T-cell therapy.

Main Results:

O-Acetyl-GD2 is emerging as a novel antigen for targeting GD2-positive cancers.
Preclinical data suggests potential therapeutic efficacy of anti-O-acetyl-GD2 antibodies.
O-Acetyl-GD2 holds relevance for developing advanced cancer immunotherapies.

Conclusions:

O-Acetyl-GD2 represents a promising new target antigen in cancer immunotherapy.
Further research into anti-O-acetyl-GD2 antibodies and CAR T-cell therapies is warranted.
O-Acetyl-GD2 may overcome limitations associated with targeting GD2.